Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Psoriasis

Psoriasis

Subtypes of Psoriasis

Plaque psoriasis 12 Erythrodermic psoriasis 1 Generalized pustular psoriasis 1 Inverse Psoriasis 1

33 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Psoriasis

289 trials tracked for Psoriasis: 148 in phase 3 or 4 and 52 with published results. The most-cited published study has 835 citations.

289Trials tracked
148Phase 3 & 4
0Recruiting
52With published results
Phase distribution
Phase 4 50 Phase 3 98 Phase 2 85 Phase 1 21 Other / NA 35
  1. Phase 3 A Phase 3 Study in Participants With Moderate to Severe Psoriasis Completed · 835 cited
  2. Phase 4 Mechanism of Action Study for Psoriasis Completed · 721 cited
  3. Phase 3 Etanercept (Enbrel®) in Psoriasis - Pediatrics Completed · 388 cited
  4. Phase 3 A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis Completed · 372 cited
  5. Phase 3 BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 295 cited
  6. Phase 3 BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment Completed · 213 cited
Show 44 more trials
  1. Phase 3 An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) Completed · 154 cited
  2. Phase 3 A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) Completed · 154 cited
  3. Phase 4 Vascular Inflammation in Psoriasis - Extension Study Completed · 146 cited
  4. Phase 4 Vascular Inflammation in Psoriasis Trial (The VIP Trial) Completed · 146 cited
  5. Phase 3 A Study in Japanese Participants With Moderate-to-Severe Psoriasis Completed · 132 cited
  6. Phase 3 Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) Completed · 130 cited
  7. Phase 3 Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis Completed · 87 cited
  8. Phase 3 A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis Completed · 86 cited
  9. Phase 3 Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis Completed · 82 cited
  10. Phase 3 A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment Completed · 81 cited
  11. Phase 3 A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis Completed · 79 cited
  12. Phase 3 A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis Completed · 71 cited
  13. Phase 3 A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) Completed · 68 cited
  14. Phase 3 Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis Completed · 55 cited
  15. Phase 3 A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis Completed · 54 cited
  16. Phase 3 A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab Completed · 54 cited
  17. Phase 3 Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy Completed · 54 cited
  18. Phase 3 BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 53 cited
  19. Phase 3 BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 53 cited
  20. Phase 3 A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) Completed · 49 cited
  21. Phase 3 A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp Completed · 47 cited
  22. Phase 4 Vascular Inflammation in Psoriasis - Apremilast Completed · 44 cited
  23. Phase 3 An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis Completed · 38 cited
  24. Phase 3 Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis Completed · 38 cited
  25. Phase 3 Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis Completed · 33 cited
  26. Phase 3 A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) Completed · 28 cited
  27. Phase 3 The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis Completed · 27 cited
  28. Phase 3 A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis Completed · 26 cited
  29. Phase 3 An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis Completed · 25 cited
  30. Phase 3 Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis Completed · 25 cited
  31. Phase 4 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy Completed · 21 cited
  32. Phase 3 A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis Completed · 20 cited
  33. Phase 3 An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age Completed · 17 cited
  34. Phase 3 Study of Secukinumab With 2 mL Pre-filled Syringes Completed · 17 cited
  35. Phase 3 A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis Completed · 15 cited
  36. Phase 4 A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies Completed · 14 cited
  37. Phase 3 A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) Completed · 13 cited
  38. Phase 3 A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis Completed · 11 cited
  39. Phase 4 A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Completed · 10 cited
  40. Phase 3 Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 8 cited
  41. Phase 3 A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis Completed · 4 cited
  42. Phase 3 An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis Completed · 3 cited
  43. Phase 3 An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea Completed · 3 cited
  44. Phase 4 A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life Completed · 2 cited

Showing the 50 most-cited and recently-updated of 289 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Network meta-analysis finds biologics superior to placebo for pediatric plaque psoriasis
Dermatology Meta-analysis
Network meta-analysis finds biologics superior to placebo for pediatric plaque psoriasis Biologic treatments help children with moderate to severe psoriasis, analysis finds
A network meta-analysis of randomized controlled trials including 1,016 pediatric psoriasis patients found all biologic therapies significan…
Biologic medicines help children with moderate to severe psoriasis achieve clear skin and better quality of life, analysis finds.
Apr 8, 2026
Bimekizumab maintains complete skin clearance in 73% of psoriasis patients at 4 years
Dermatology RCT
Bimekizumab maintains complete skin clearance in 73% of psoriasis patients at 4 years Can psoriasis treatment keep skin clear for years? New data suggests it might
A pooled analysis of phase 3 trials and open-label extension in 503 psoriasis patients found 73.0% of those achieving complete clearance at …
After four years on bimekizumab, about 73% of patients with psoriasis kept their skin completely clear, suggesting the treatment may help re…
Apr 6, 2026
Oral ME3183 shows higher PASI-75 response rates than placebo in moderate to severe plaque psoriasis trial
Dermatology RCT
Oral ME3183 shows higher PASI-75 response rates than placebo in moderate to severe plaque psoriasis trial Could a new pill help clear stubborn psoriasis skin plaques?
A 16-week randomized controlled trial in 132 patients with moderate to severe plaque psoriasis found higher proportions achieving ≥75% PASI …
A new oral pill helped over 60% of patients with moderate to severe psoriasis clear skin plaques significantly better than a placebo in a re…
Apr 1, 2026
Guselkumab Shows Improvement in Inverse Psoriasis in Single Case Report
Dermatology Guideline
Guselkumab Shows Improvement in Inverse Psoriasis in Single Case Report Can a psoriasis drug help with a rare, hard-to-treat skin condition?
A case report and literature review describes a 48-year-old male with inverse psoriasis who showed marked improvement in cutaneous lesions a…
A single patient with hard-to-treat inverse psoriasis found marked relief in itching and skin lesions after just three injections of a newer…
Frontiers Apr 1, 2026
Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28
Dermatology Phase II
Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28 Could a new psoriasis treatment work better by targeting two inflammation sources at once?
A Phase 2a, multicenter, randomized, subject- and investigator-blind study investigated the pharmacokinetics, pharmacodynamics, and safety o…
A new psoriasis drug targets two inflammation sources to see if it works better for thick, scaly skin patches in adults.
CT.gov Mar 30, 2026
Phase 3 trial compares bimekizumab to placebo and ustekinumab for moderate to severe plaque psoriasis
Rheumatology Phase III
Phase 3 trial compares bimekizumab to placebo and ustekinumab for moderate to severe plaque psoriasis Can a new psoriasis drug outperform an established treatment?
A phase 3 randomized controlled trial enrolled 567 adults with moderate to severe chronic plaque psoriasis to compare bimekizumab against pl…
A new psoriasis drug called bimekizumab is being tested against existing treatments in a major trial involving 567 adults to see if it helps…
CT.gov Mar 30, 2026
Phase 3 trial of bimekizumab versus placebo in 435 adults with moderate to severe plaque psoriasis
Dermatology Phase III
Phase 3 trial of bimekizumab versus placebo in 435 adults with moderate to severe plaque psoriasis Can a new drug help people with moderate to severe plaque psoriasis?
A phase 3 randomized controlled trial evaluated bimekizumab versus placebo in 435 adults with moderate to severe chronic plaque psoriasis.
A new drug tested in a large study aims to help clear skin for people with moderate to severe plaque psoriasis.
CT.gov Mar 30, 2026
Sliding Cupping Therapy Matches NBUVB in Psoriasis Severity Reduction at 8 Weeks
Dermatology RCT
Sliding Cupping Therapy Matches NBUVB in Psoriasis Severity Reduction at 8 Weeks Could Sliding Cupping Therapy Be a Game-Changer for Psoriasis Patients?
In a RCT with 60 psoriasis patients, sliding cupping showed similar efficacy to NBUVB in reducing PASI scores by 62.4% vs. 66.9% (P=.526).
Sliding cupping therapy improved psoriasis symptoms just as well as standard light treatment, offering a viable alternative for patients see…
NEJM Mar 27, 2026
Psoriasis Linked to 24% Increased Stroke Risk, Especially in Severe Cases
Neurology Meta-analysis
Psoriasis Linked to 24% Increased Stroke Risk, Especially in Severe Cases Does Having Psoriasis Put You at Greater Risk for a Stroke?
Meta-analysis of 18 studies shows psoriasis patients have a 24% higher stroke risk (HR 1.24, 95% CI: 1.15-1.35, P<.05), with severe cases at…
People with severe psoriasis face a 36% higher risk of stroke, while even mild cases show a 9% increase in risk compared to those without th…
NEJM Mar 27, 2026

Questions about Psoriasis

Are there regional differences in health issues for people with psoriasis?

Yes, regional differences exist in psoriasis-related health issues, including comorbidities, treatment patterns, and healthcare access, as shown by studies from North America, Europe, Asia, and Africa.

Full answer →
Is secukinumab effective for Chinese patients with psoriatic arthritis?

Yes, secukinumab is effective for Chinese patients with psoriatic arthritis, with real-world data and cost-effectiveness analyses supporting its use.

Full answer →